Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)

Blood (2024) 144 (Supplement 1): 3531.

https://doi.org/10.1182/blood-2024-203251

Published: 2024

Journal Articles

Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Blood (2024) 144 (Supplement 1): 305.

https://doi.org/10.1182/blood-2024-194716

Published: 2024

Journal Articles

Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)

Blood (2024) 144 (Supplement 1): 4869.

https://doi.org/10.1182/blood-2024-206887

Published: 2024

Journal Articles

Zanubrutinib Is Effective in the Treatment of Patients with Waldenström's Macroglobulinemia and Bing-Neel Syndrome: A Retrospective Multicenter Study

Julia Bannatyne Undabeitia, Elia Barrio, Ruben Fernandez Alvarez, Anabel Teruel, María José Terol, Sheila Bodelon, Eduardo Rios Herranz, Victor Marco, Fernando Carnicero, Leonor Perez, Angel Mayorales, Iñigo Romon, Sara Fernandez-Luis, Enrique M. Ocio, Arancha Bermúdez

Blood (2024) 144 (Supplement 1): 1642.

https://doi.org/10.1182/blood-2024-211056

Published: 2024

Journal Articles

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Blood (2023) 142 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2023-189581

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplants for Patients with Hodgkin disease: A Comparative Study of the LWP EBMT

Blood (2023) 142 (Supplement 1): 4975.

https://doi.org/10.1182/blood-2023-179829

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Blood (2023) 142 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2023-174115

Published: 2023

Journal Articles

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Blood (2023) 142 (Supplement 1): 1.

https://doi.org/10.1182/blood-2023-186963

Published: 2023

Journal Articles

Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2022) 140 (Supplement 1): 4848–4850.

https://doi.org/10.1182/blood-2022-166166

Published: 2022

Journal Articles

Progression Risk and Long-Term Survival Trends of 915 Patients with Asymptomatic IgM Monoclonal Gammopathy

David F. Moreno, Cristina Jiménez, Fernando Escalante Barrigón, Elham Askari, Mario Arnao, Ángela Heredia, Magdalena Alcalá, Arancha Bermúdez, Ana Saus Carreres, Maria Casanova, Luis Palomera, Cristina Motllo, Ricarda Belen Garcia Sanchez, Ramón García-Sanz, Carlos Fernández De Larrea

Blood (2022) 140 (Supplement 1): 259–260.

https://doi.org/10.1182/blood-2022-163008

Published: 2022

Journal Articles

A Second Haploidentical Stem Cell Transplantation (HAPLO-SCT2) after Relapse from First Haplo-SCT Is Feasible and Produces Results That Are Comparable to Data Reported after Second SCT in an HLA-Matched Setting - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Giuliano Filippini Velazquez, Myriam Labopin, Johanna Tischer, Emanuele Angelucci, Alexander D. Kulagin, Piero Galieni, Arancha Bermúdez, Claude-Eric Bulabois, Nicolaus Kröger, José Luis Díez-Martin, Arnon Nagler, Christoph Schmid, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 7744–7746.

https://doi.org/10.1182/blood-2022-160229

Published: 2022

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Blood (2022) 140 (Supplement 1): 400–402.

https://doi.org/10.1182/blood-2022-159009

Published: 2022

Journal Articles

Primary Central Nervous System Involvement at Initial Diagnosis Remains an Independent Risk Factor for Relapse in Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation in CR1

Blood (2021) 138 (Supplement 1): 2901.

https://doi.org/10.1182/blood-2021-149695

Published: 2021

Journal Articles

Ponatinib and Chemotherapy in Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial

Josep-Maria Ribera, Olga Garcia, Jordi Ribera, Pau Montesinos, Isabel Cano, Pilar Martínez, Jordi Esteve, Daniel Esteban, María García-Fortes, Natalia Alonso, José González-Campos, Arancha Bermúdez, Anna Torrent, Eulàlia Genescà, Santiago Mercadal, Joaquín Martínez-López, Ramon Garcia-Sanz

Blood (2021) 138 (Supplement 1): 1230.

https://doi.org/10.1182/blood-2021-148310

Published: 2021

Journal Articles

Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT

Blood (2021) 138 (Supplement 1): 3953.

https://doi.org/10.1182/blood-2021-150892

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Blood (2021) 138 (Supplement 1): 3890.

https://doi.org/10.1182/blood-2021-151087

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC

Blood (2021) 138 (Supplement 1): 3913.

https://doi.org/10.1182/blood-2021-150835

Published: 2021

Journal Articles

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Josep-Maria Ribera, Mireia Morgades, Juana Ciudad, Pau Montesinos, Jordi Esteve, Eulàlia Genescà, Pere Barba, Jordi Ribera, Irene García-Cadenas, María José Moreno, Daniel Martínez-Carballeira, Anna Torrent, Pilar Martínez-Sánchez, Silvia Monsalvo, Cristina Gil, Mar Tormo, María Teresa Artola, Marta Cervera, José González-Campos, Carlos Rodríguez, Arancha Bermúdez, Andrés Novo, Beatriz Soria, Rosa Coll, María-Luz Amigo, Aurelio López-Martínez, Rosa Fernández-Martín, Josefina Serrano, Santiago Mercadal, Antònia Cladera, Alberto Giménez-Conca, María-Jesús Peñarrubia, Eugènia Abella, Ferran Vall-llovera, Jesús-María Hernández-Rivas, Antoni Garcia-Guiñon, Juan-Miguel Bergua, Beatriz de Rueda, María-José Sánchez-Sánchez, Alfons Serrano, María Calbacho, Natalia Alonso, Jose-Ángel Méndez-Sánchez, Raimundo García-Boyero, Matxalen Olivares, Susana Barrena, Lurdes Zamora, Isabel Granada, Ludovic Lhermitte, Evarist Feliu, Alberto Orfao

Blood (2021) 137 (14): 1879–1894.

https://doi.org/10.1182/blood.2020007311

Published: 2021

Includes: Supplemental data

Journal Articles

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment

Josep-Maria Ribera, Olga García, Pau Montesinos, MD PhD, Pilar Martinez, MD, Jordi Esteve, Daniel Esteban, María José Moreno, MD, Natalia Alonso, José González-Campos, MD, Arancha Bermúdez, MD, Anna Torrent, Joaquin Martinez-Lopez, MD, Santiago Mercadal, MD, Ramon Garcia-Sanz

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137489

Published: 2020

Journal Articles

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Lucrecia Yanez San Segundo, MD PhD, Noemi Fernandez Escalada, MD, Arancha Bermúdez, MD, Guillermo Martín Sánchez, MD, Sara García Avila, MD, Mónica López Duarte, MD, Mercedes Colorado, MD, Iñigo Romon, MD PhD, Carlos Richard, MD, Enrique M. Ocio, MD PhD

Blood (2019) 134 (Supplement_1): 5655.

https://doi.org/10.1182/blood-2019-130731

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)

Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)

Zanubrutinib Is Effective in the Treatment of Patients with Waldenström's Macroglobulinemia and Bing-Neel Syndrome: A Retrospective Multicenter Study

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplants for Patients with Hodgkin disease: A Comparative Study of the LWP EBMT

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Progression Risk and Long-Term Survival Trends of 915 Patients with Asymptomatic IgM Monoclonal Gammopathy

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Primary Central Nervous System Involvement at Initial Diagnosis Remains an Independent Risk Factor for Relapse in Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation in CR1

Ponatinib and Chemotherapy in Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial

Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only